Irish medtech company OncoAssure has entered a research partnership with the Icahn School of Medicine at Mount Sinai, New York, to conduct a validation study using its Prostate Cancer Test alongside curated clinical samples from the hospital.

The OncoAssure Prostate Test, designed for men diagnosed with localised prostate cancer, assesses the risk of aggressive disease and recurrence, and can be applied post-biopsy or post-surgery. The study will focus on low- to intermediate-risk prostate cancer cases to evaluate the prognostic value of the test beyond standard clinical and pathological information.

“This work will build on prior studies conducted in collaboration with Lund University in Sweden,” said Des O’Leary, CEO of OncoAssure Ltd. “By applying our innovative OncoAssure Prostate technology in collaboration with the Icahn School of Medicine, we aim to generate additional evidence supporting the potential of the OncoAssure Prostate Cancer Test to both reduce unnecessary interventions and provide critical lead time for treating the most aggressive tumors.”

The research will be led by Ash Tewari, MD, alongside cancer researchers Sujit S. Nair, PhD, and Dimple Chakravarty, PhD. Professor Tewari noted, “Our collaboration with OncoAssure is focused on rigorous clinical evaluation of the OncoAssure Prostate Cancer Test to better understand its potential role in patient management and how it could provide meaningful benefit to our patients.”

The test integrates advanced genomic insights with the widely used CAPRA (Cancer of the Prostate Risk Assessment) score, enabling seamless incorporation into existing care pathways.

By combining clinical and genomic data, OncoAssure Prostate provides more precise prognostic assessments, allowing clinicians to personalise treatment decisions and identify aggressive cancers more reliably.

Discover how OncoAssure’s test could transform prostate cancer treatment decisions in this groundbreaking study in the full story.

Photo credits to OncoAssure’s LinkedIn/Vincent Hoban, UCD